However, the patients who had PD‐IDC were more likely to have more aggressive pathology characteristics, such as a higher histologic grade (61.5% of PD‐IDC patients vs 39.0%, of IDC alone patients had Grade III/IV lesions, P < 0.001), more advanced AJCC stage (29.3% vs 12.1%, respectively, had stage III disease, P < 0.001), lower HR‐positive ratio (55.7% vs 79.4%, respectively, had ER + or PR + cancer, P < 0.001), and higher HER2‐positive ratio (63.5% vs 16.7%, respectively, P < 0.001), than the IDC alone patients. This evidence concerns the gene ERBB2 and cancer.